Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Goy on Durable Responses With Brexu-cel in the ZUMA-2 Trial in MCL

February 13th 2023

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma

February 7th 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib

February 7th 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

Dr. Gandhi on Key Interim Results From the SGN35-027 Trial in Hodgkin Lymphoma

February 1st 2023

Mitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.

Ibrutinib Plus Chemo Induction Followed by Ibrutinib Maintenance Could Be New Standard in MCL

January 31st 2023

Martin Dreyling, MD, discusses the safety and efficacy data from the TRIANGLE study done in patients with previously untreated MCL who are younger than 66 years, and the impact of these results on the use of ASCT in this population.

Pirtobrutinib’s Approval Addresses Unmet Need in MCL Treatment Paradigm

January 31st 2023

Michael L. Wang, MD, discusses the efficacy of the noncovalent BTK inhibitor pirtobrutinib, as well as safety data from the phase 1/2 BRUIN trial in mantle cell lymphoma.

BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

January 31st 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL

January 31st 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Dr. Phillips on the FDA Approval of Pirtobrutinib in MCL

January 27th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 27th 2023

The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a BTK inhibitor.

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

Autologous stem cell transplant had no effect on real-world time to next treatment and overall survival compared with maintenance rituximab following induction with bendamustine and rituximab or R-CHOP, for patients with mantle cell lymphoma according to findings from a retrospective study.

Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

January 24th 2023

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL

January 24th 2023

Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.

Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma

January 17th 2023

A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.

Overview of Mantle Cell Lymphoma and First-Line Treatment Options

January 17th 2023

Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

R-DHAP plus high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous stem cell transplant demonstrated sustained time to treatment failure and overall survival benefits vs R-CHOP plus standard myeloablative radiochemotherapy and ASCT in patients with mantle cell lymphoma aged 65 years and younger.

Dr. Dreyling on Key Efficacy Results From the TRIANGLE Study in MCL

January 16th 2023

Martin Dreyling, MD, discusses key efficacy results from the phase 3 TRIANGLE study in mantle cell lymphoma.

Frontline Zanubrutinib Plus Rituximab Followed by Short-Course R-DHAOx Generates Preliminary Efficacy in MCL

January 15th 2023

First-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin elicited responses in patients with mantle cell lymphoma, according to preliminary results from the phase 2 CHESS trial.

Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL

January 13th 2023

Treatment with brexucabtagene autoleucel produced ongoing responses in patients with mantle cell lymphoma with high-risk disease characteristics, including those with a lower ECOG performance score and tumor burden and less frequent prior use of bridging or platinum therapy.

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

The FDA has granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma